Anteris Technologies Global Corp. Common Stock (AVR)

About Anteris Technologies Global Corp. Common Stock

Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 133 institutions reported holding AVR, with 65.0 million shares worth $639.9 million in aggregate. The largest reported holder was L1 Capital Pty, with 7.8 million shares worth $76.7 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions